date:Dec 04, 2019
t health.
Containing highly concentrated and purified eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), Hepacor is uniquely designed to correct the nutritional deficiency of patients with NAFLD and can address a buildup of fat in the liver, known as steatosis, in NAFLD patients.
NAFLD is one of the most common forms of chronic liver disease worldwide. Studies have shown that NAFLD patients suffer from EPA and DHA deficiency. A previous BASF-endorsed clinical study showed that Hepaco